Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study

Table 2 Surgery-related data of 15 patients undergoing neoadjuvant therapy for pancreatic cancer

Variables
Tumor location, n (%)
Head of the pancreas	8 (53.3)
Pancreatic body and tail	7 (46.7%)
Surgical procedure, n (%)
L-RAMPS	7 (46.7)
LPD	8 (53.3)
Vascular resection and reconstruction, n (%)	1 (6.67)
Operative time (min)
L-RAMPS	326.43 ± 49.14
LPD	444.38 ± 68.63
Intraoperative blood loss (mL)
L-RAMPS	435.71 ± 262.54
LPD	343.75 ± 145.01
Intraoperative blood transfusion, n (%)
L-RAMPS	2 (13.35)
LPD	2 (13.35)
Conversion, n (%)	0 (100)
Complications, n (%)
Jaundice	1 (6.67)
Grade B POPF	1 (6.67)
Postoperative hospital stay (d)	13 (12-14)1
Follow-up duration (mo)	7 (5-16)1
Recurrence/metastasis, n (%)
Liver metastasis	3 (20)
Lymph node metastasis	1 (6.67)
Mortality within the follow-up period, n (%)	1 (6.67)

¹Data are presented as the median (interquartile range).

L-RAMPS: Laparoscopic radical antegrade modular pancreatosplenectomy; LPD: Laparoscopic pancreatoduodenectomy; POPF: Postoperative pancreatic fistula.